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chemotherapyAbstract Aim: To investigate whether adding bevacizumab to neoadjuvant carboplatin-
paclitaxel (CP) helps achieve optimal debulking, measured by complete resection rate
(CRR) at interval debulking surgery (IDS), in patients with initially unresectable International
Federation of Gynecology and Obstetrics stage IIIC/IV ovarian, tubal or peritoneal adenocar-
cinoma.
Methods: Multicentre, open-label, non-comparative phase II study. Ninety-five patients ran-
domised (2:1) to receive four cycles of neoadjuvant CP 3 concomitant cycles of bevacizumab
15 mg/kg (BCP) followed by IDS. Primary objective is to evaluate the CRR at IDS in the BCP
group (reference CRR rate defined as 45% CRR). A stopping rule based on bevacizumab-
related adverse events (AEs) of special interest was implemented.
Results: In the BCP group (NZ 58), IDS was performed in 40 (69%) patients, of whom 85%
had a complete resection. The CRR of this group was therefore 58.6% (34 patients), statisti-
cally over pre-defined 45%. The CRR in the CP group was 51.4%: 22 (60%) patients under-
went IDS (85% had a complete resection). Grade 3 adverse events occurred in 62% of the
BCP-treated patients and 63% of the CP-treated patients: mainly blood and lymphatic,
gastrointestinal and vascular disorders, without more toxicity with BCP. Postoperative com-
plications (mainly wound, infectious and gastrointestinal complications) occurred in 28% and
36% of the patients, respectively. The pre-specified safety stopping rule was not reached.
Conclusion: The primary objective was met as the CRR with BCP was significantly higher
than the reference rate. Bevacizumab may be safely added to a preoperative program in pa-
tients deemed non-optimally resectable, whatever the final surgical decision. Bevacizumab’s
role in this setting should be further investigated.
ª 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Primary debulking surgery followed by adjuvant plat-
inum- and taxane-based chemotherapy is the corner-
stone of treatment for ovarian cancer. In patients with
advanced ovarian cancer, neoadjuvant chemotherapy
followed by interval debulking surgery (IDS) offers
similar overall survival (OS) benefits as primary
debulking surgery and is better tolerated [1e3]. An
EORTC study investigated debulking surgery followed
by six courses of platinum-based chemotherapy versus
three courses of platinum-based neoadjuvant chemo-
therapy followed by IDS and three further courses of
platinum-based chemotherapy [1]. Residual disease was
<1 cm in 41.6% of the patients after primary debulking
and in 80.6% of the patients after IDS. Median OS was
similar between groups. Adverse event (AE) rates and
mortality tended to be higher after primary debulking
surgery. Based on these results, neoadjuvant carboplatin
and paclitaxel (CP) chemotherapy is the standard
treatment before IDS in patients with non-optimally
resectable ovarian cancer. Regardless of which debulk-
ing strategy is used, the absence of residual tumour after
surgery is the most important independent prognostic
factor for OS.
Two randomised phase III trials (GOG218 [4] and
ICON7 [5]) in the first-line ovarian cancer setting re-
ported that adding bevacizumab to CP, followed by
maintenance bevacizumab monotherapy, was more
effective than chemotherapy alone at improvingresponse rates and progression-free survival after initial
surgery. For patients with non-optimal initial surgery
who are at high risk of progression, the addition of
bevacizumab to CP also improved OS [5].
In this study, we hypothesised that adding bev-
acizumab to neoadjuvant CP chemotherapy would help
to achieve optimal debulking rate at IDS, as measured
by the complete resection rate (CRR), in patients with
initially unresectable International Federation of Gy-
necology and Obstetrics (FIGO) stage IIIC/IV ovarian,
tubal or peritoneal adenocarcinoma, without increasing
the incidence of postoperative complications.2. Patients and methods
2.1. Study design
The Avastin Neoadjuvant Therapy in patients with
Advanced ovarian cancer initialLY unresectAble
(ANTHALYA), multicentre, open-label, non-compara-
tive phase II study, randomised patients 2:1 to receive
four cycles of neoadjuvant CP chemotherapy with (BCP
group) or without (CP group) three cycles of bev-
acizumab 15 mg/kg (Fig. 1). Stage IV disease, necessity
of extensive/multiple bowel resection, high Fagotti
score, extensive miliary peritoneal carcinomatosis,.
usually classified patients as deemed unresectable. The
extent of carcinomatosis was evaluated laparoscopically
before neoadjuvant therapy and before IDS. IDS was
Fig. 1. ANTHALYA study design. AUC, area under the curve; C, cycle; CP, carboplatin-paclitaxel chemotherapy; BCP, bevacizumab
plus CP; FIGO, International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery.
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Adjuvant chemotherapy began 4e5 weeks after surgery
for four cycles with bevacizumab reintroduced at cycle
six (for a maximum of 26 cycles). All patients consented
to serial blood sampling for further analyses. The trial
was conducted at study sites with teams experienced in
the multidisciplinary treatment of ovarian cancer.
The study was approved by the independent ethics
committee of each participating centre and conducted in
accordance with Good Clinical Practice guidelines and
the Declaration of Helsinki. Written informed consent
was obtained from all patients before screening. The
trial is registered (clinicaltrials.gov: NCT01739218).
2.2. Patients
Eligible patients were women aged 18 years with his-
tologically confirmed, chemotherapy-naı¨ve, high-risk
FIGO stage IIIC/IV epithelial ovarian carcinoma, fallo-
pian tube carcinoma or primary peritoneal carcinoma
(deemed ineligible for primary complete debulking sur-
gery by a surgeon experienced in the management of
ovarian cancer during a laparoscopic procedure); an
Eastern Cooperative Oncology Group performance sta-
tus (ECOG-PS) 0e2; life expectancy 3 months; and
eligible for CP chemotherapy. To ensure somehow a de-
gree of inter-tumour homogeneity, women with ovarian
tumourwith lowmalignant potential, mucinous and clear
cell ovarian cancer or carcinosarcoma, and thosewho had
undergone previous systemic therapy for ovarian cancer,
prior radiotherapy or major surgery were excluded
(Appendix A details other exclusion criteria).
2.3. Treatment
The treatment period for each patient was approximately
21 months. Each cycle lasted 3 weeks. In the neoadjuvantperiod, all patients received area under the curve 5 mg/
mL/min of carboplatin and 175 mg/m2 of paclitaxel
intravenously on Day 1 (cycles 1e4); patients in the BCP
group received 15 mg/kg of bevacizumab administered
intravenously every 3 weeks (q3w) on Day 1 (cycles 1e3)
in addition to CP. In the adjuvant period, all patients
received area under the curve 5 mg/mL/min of carbo-
platin and 175 mg/m2 of paclitaxel intravenously q3w on
Day 1 (cycles 5e8), and all patients received 15 mg/kg of
bevacizumab intravenously q3w on Day 1 (cycles 6e26).
Bevacizumab, carboplatin, and paclitaxel were adminis-
tered according to the protocol or until disease progres-
sion, the occurrence of an unacceptable toxicity, or at the
patient’s or treating physician’s request (Fig. 1).
2.4. Study objectives
The primary objective was to evaluate the benefit of
neoadjuvant bevacizumab and chemotherapy assessed
by the CRR at IDS (primary endpoint). The secondary
objective was to evaluate the safety profile of bev-
acizumab added to neoadjuvant and adjuvant chemo-
therapy. The final analysis of the primary endpoint was
conducted at the interim analysis of the trial after all
patients had completed the post-IDS follow-up
assessment.
2.5. Study assessments
Physical examination, vital signs, laboratory safety as-
sessments, and recording of AEs according to the Na-
tional Cancer Institute’s cancer toxicity criteria for AEs
(NCI-CTCAE; v4.03), were performed by the Investi-
gator. Additional safety assessments (in line with local
standard of care or those that were symptom-directed)
were undertaken at the discretion of the treating
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standardised terms according to the industry standard
Medical Dictionary for Regulatory Activities. Events
were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events
(NCI-CTCAE) version 4.03. Multiple occurrences of
each event per patient were counted once at themaximum
severity. Left ventricular ejection fraction was assessed at
baseline and in case of symptomatic cardiac failure in
which case it was repeated every 3 weeks until the reso-
lution or stabilisation of the event. An independent safety
data monitoring board regularly reviewed all safety data
and a stopping rule was implemented during the neo-
adjuvant period, at IDS, and during 30 d following IDS in
the BCP group if20% of the patients experienced severe
surgical or general complications related to bevacizumab
(described in Appendix B).
2.6. Statistical method
The rate of complete resection at IDS with 95% one-
sided CI was assessed using Pearson-Clopper’s exact
method [6]. Complete resection was defined as the
removal of all macroscopic residual tumour (complete-
ness of cytoreduction [CC] score of zero). Patients not
having IDS performed were considered as failure.
In the BCP group, the sample size calculation was
based on a one-step phase II study using the Fleming
A’Hernmethod [7]. Vergote et al. [2] had shown aCRRof
46.3% (51.2% in patients with IDS) for patients with
FIGO stage IIIC/IV ovarian cancer after neoadjuvant
platinum-based chemotherapy. Therefore a CRR of 45%
(null hypothesis: P  45%) was considered insufficient
evidence for the benefit of adding bevacizumab to
chemotherapy (BCP group) in the neoadjuvant setting
and a CRR of 65% (alternative hypothesis: P 65%) was
considered as the minimal target of clinical efficacy.
Accepting a type 1 error a Z 0.05 one-sided and type 2
error bZ 0.10, 54 evaluable patients were required in the
BCP group. Proof of potential efficacy was considered if
31 patients had a CC score of 0. As the CP group was
considered the ‘calibration group’ for the CRR and no
comparison between treatments was expected, we used a
2:1 randomisation design. Therefore, the calibration
group was planned to include 27 patients treated without
bevacizumab in the neoadjuvant setting. Assuming a 10%
drop out rate, a total of 90 patients were required: 60 in
the BCP group and 30 in CP group. As 58 patients were
ultimately included in BCP group, 33 patients with a CC
score of 0 were required to reject the null hypothesis
(Fig. 2A), with an actual type 1 error aZ 0.046 one-sided
and type 2 error bZ 0.08 (power of 92%) [8].
Efficacy and safety analyzes were performed in pa-
tients having received at least one administration of
treatment. Efficacy analyses were performed in the
modified intention-to-treat (mITT) population accord-
ing to the assigned group at randomisation. Safetyanalyses were performed according to the actual treat-
ment received (safety population). The primary
endpoint was also assessed in two sensitivity analyses in
the mITT population for whom IDS was performed,
and the mITT population who received at least two
cycles of bevacizumab.3. Results
3.1. Patients
Between January 2013 and June 2014, 205 patients
were screened at 15 French study sites, of which 95
were included in the mITT population (37 [39%] in the
CP group and 58 [61%] in the BCP group; Fig. 3).
Fifty-five (58%) patients received at least one treatment
with bevacizumab and chemotherapy and 40 (42%)
patients received only chemotherapy (safety pop-
ulations). Baseline patient and disease characteristics
were balanced between groups (Table 1). Median age
was 63 years (range 33e87 years), 94% of the patients
had ECOG-PS 0/1, and 70% and 30% had FIGO stage
IIIC and IV tumours, respectively. More than 90% of
the patients had high grade and serous histological
subtype tumours.
Mean neoadjuvant treatment exposure was 2.7
months (standard deviation [SD]: 0.5 months) and was
balanced between groups. Mean bevacizumab exposure
in the BCP group was 2.0 months (SD 0.3 months).
Overall, 90% of the patients received all four planned
neoadjuvant CP treatment cycles and 87% of the pa-
tients in the BCP group received all three cycles of
bevacizumab. Eight (22%) patients from the CP group
and 10 (17%) patients from the BCP group withdrew
prematurely from the study (Fig. 3).3.2. Efficacy
Interval debulking surgery was performed in 62 patients
(40 [69%] in the BCP group and 22 [60%] in the CP
group; Table 2). The mean times from first study treat-
ment administration to IDS laparoscopy and surgery
were comparable between the two groups. Unresectable
tumour assessed by laparoscopy before IDS was the
most common reason for surgery not being performed
in both groups (Table 2).
The CRR at IDS in BCP-treated patients was 58.6%
(34 patients) with a one-sided lower 95% confidence
interval of 47.0% (Fig. 2B). Consequently, the CRR was
significantly higher than the reference rate. In a sensi-
tivity analysis limited to patients who underwent IDS
(n Z 40), the CRR at IDS in BCP-treated patients was
85.5%. In patients from the mITT population who had
at least two cycles of bevacizumab (n Z 52), the CRR
was 63.5% and in the safety population the CRR was
61.8%. The CRR in CP-treated patients in the mITT
Fig. 2. (A) Statistical hypothesis and sample size for the primary criterion (Fleming A’Hern design). Four different situation are illus-
trated, two which indicate potential proof of efficacy (yellow diamonds and bars) and two which show insufficient evidence for efficacy
(blue diamonds and bars; B) Results of the primary endpoint and sensitivity analyses in the mITT population who received at least two
cycles of bevacizumab and the population of patients for whom IDS was performed. CP, carboplatin-paclitaxel chemotherapy; CR(R),
complete resection (rate); BCP, bevacizumab plus CP; H0, null hypothesis; H1, alternative hypothesis; IDS, interval debulking surgery;
mITT, modified intent-to-treat.
R. Rouzier et al. / European Journal of Cancer 70 (2017) 133e142 137population was 51.4% and 86.4% in CP-treated patients
who underwent IDS (n Z 22).
3.3. Safety
Overall, 94 (99%) patients experienced at least one AE
before or during the IDS period (Table 3). Serious AEs
(SAEs) were more frequent in the CP group versus the
BCP group. The most common treatment-emergent
SAEs in the CP and BCP groups were gastrointestinal
disorders (13% versus 7%, respectively), infections and
infestations (8% versus 9%, respectively), and respira-
tory disorders (10% versus 2%, respectively). Other
SAEs seen in BCP-treated patients were: blood and
lymphatic disorders (5%), vascular disorders (4%), gen-
eral disorders (2%) and injury/procedural complications
(2%). In the overall population, 59 (62%) patients
experienced one AE of grade 3; these were blood andlymphatic (28%), gastrointestinal (13%), vascular (11%),
and general disorders (10%), and infections and in-
festations (6%). One AE lead to death in the CP group; a
bilateral pneumopathy after the third cycle.
Of the 62 patients who had IDS, 32 (52%) patients
had at least one abnormal examination at 30 d post-IDS
(both arms combined): 42% were abdominal, 18%
gynaecological, and 8% gastrointestinal (Table 4). The
overall mean (SD) duration of hospitalisation was
13  7 d and the mean (SD) duration of hospital-
isation in the intensive care unit was 3.5  3.2 d. In total,
27 (44%) patients needed blood transfusions following
surgery. Postoperative complications occurred in 19
(31%) patients. Three (5.5%) patients in the BCP group
experienced four surgical complications (all grade 4
haemorrhages) and one general complication (grade 3
thromboembolic event) of special interest to
bevacizumab.
Fig. 3. CONSORT flow diagram. CP, carboplatin-paclitaxel chemotherapy; BCP, bevacizumab plus CP; mITT, modified intent-to-treat;
SAF, safety population.
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This randomised study investigated neoadjuvant CP
chemotherapy with and without bevacizumab followed
by IDS in women with advanced ovarian or primary
peritoneal cancer deemed unresectable in primary
debulking surgery. We included a calibration group with
conventional CP as we believed that the surgical effort
would be the main driver of complete resection.
Neoadjuvant chemotherapy with bevacizumab ach-
ieved a CRR at IDS of 58.6% with a lower confidence
limit of 47.0%, significantly higher than the threshold of
45% established based on the CRR rate reported in the
EORTC study of neoadjuvant platinum-based chemo-
therapy followed by IDS (46.3%) [2]. Therefore, theprimary objective of our study was met indicating proof
of potential efficacy of the BCP combination. The CRR
was high in patients who underwent IDS after neo-
adjuvant therapy (85.5%). The complication rate was
acceptable, demonstrating the feasibility of adminis-
tering bevacizumab in the neoadjuvant setting.
All patients had FIGO stage IIIC/IV ovarian cancer.
At baseline, metastatic lesions were >10 and >5 cm in
diameter in 28% and 63% of patients, respectively and
were in line with the EORTC and CHORUS study
populations [2,3], although the frequency of serous tu-
mours (95%) was greater than in the EORTC study
(58%). These broad similarities in patient characteristics
justify the use of the CRR from the EORTC study as the
reference rate in our statistical hypothesis.
Table 1
Baseline and disease characteristics (mITT).
Carboplatin þ paclitaxel
(CP, n Z 37)
Bevacizumab þ carboplatin þ
paclitaxel (BCP, n Z 58)
Total (n Z 95)
Age (years)
Mean  SD 61  10 62  10 62  10
Median (range) 63 (39e79) 63 (33e87) 63 (33e87)
ECOG performance status, n (%) 1 missing
0 e Fully active 15 (42) 21 (36) 36 (38)
1 e Ambulatory 18 (50) 35 (60) 53 (56)
2 e Restricted 3 (8) 2 (4) 5 (6)
FIGO stage, n (%)
IIIC 24 (65) 43 (74) 67 (70)
IV 13 (35) 15 (26) 28 (30)
Origin of cancer, n (%) 4 missing 5 missing 9 missing
Ovary (epithelial) 30 (91) 52 (98) 82 (95)
Primary peritoneal 3 (9) 1 (2) 4 (5)
Histological subtype, n (%)
Serous 36 (97) 54 (93) 90 (95)a
Endometrioid 0 1 (2) 1 (1)
Serous/endometrioid 0 1 (2) 1 (1)
Otherb 1 (3) 2 (3) 3 (3)
Histological grade, n (%) 1 missing 5 missing 6 missing
Well differentiated (Low grade) 5 (14) 0 5 (6)
Poorly differentiated (High grade)c 31 (86) 53 (100) 84 (94)
Tumour assessment
1 target lesion 50 mm, n (%) 26 (70) 34 (59) 60 (63)
1 target lesion 100 mm, n (%) 11 (30) 16 (28) 27 (28)
CA-125
Mean  SD, U/mL 3838  9331 3942  7003 3902  7943
Median (range), U/mL 1281 (44e54,152) 1008 (128e37,537) 1045 (44e54,152)
500 U/mL, n (%) 12 (32) 16 (28) 28 (30)
>500 U/mL, n (%) 25 (68) 42 (72) 67 (70)
Abbreviations: CA-125, Cancer Antigen 125; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and
Obstetrics; mITT, modified intent-to-treat; SD, standard deviation.
Missing values are excluded from the calculation of percentages.
a Eighty-one of 90 patients (90%) had high grade serous tumour (one patient had serous/endometrioid tumour).
b Two patients with ‘adenocarcinoma not specified’ and one patient with mucinous tumour (initially unclassified).
c Nine patients were grade 2, 75 patients were grade 3.
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cialised centres. This may explain the relatively high
CRR (51.4%) also observed in the CP group. While
surgical effort was heterogeneous in the EORTC and
CHORUS studies and was considered a limitation
[2,3], surgical interventions in our study were typically
more aggressive. We performed twice the number of
bowel resections and four times the number of supra-
colic surgeries and fewer patients (65%) were
considered eligible for IDS after neoadjuvant
chemotherapy than in the EORTC study (88%) [2].
This suggests the decision to perform IDS is more
adequately taken by trained surgeons working in
experienced centres. Our good results may also partly
be due to a highly selected, homogeneous population
presenting mainly with high grade, chemosensitive
ovarian carcinoma. This study is a phase II study and
warrants additional studies to answer specific points
as the centre effect.
Anti-angiogenic therapy with bevacizumab in the
neoadjuvant setting could potentially increase the rate ofoperative and postoperative complications. The rate of
pre-specified complications in bevacizumab-treated pa-
tients (5.5% overall) did not exceed the pre-defined 20%
probability of toxicity threshold at any point during the
study (thus the stopping rule for toxicity was not
implemented) and was similar to that observed in the
EORTC study, where 4.1% of the patients experienced
grade 3/4 haemorrhage after three courses of neo-
adjuvant chemotherapy and IDS [2]. Importantly, the
BCP regimen also did not increase the risk of periop-
erative complications in patients who ultimately did not
undergo IDS.
Notably, patients in our study received four courses
of neoadjuvant chemotherapy versus three in the
EORTC and the CHORUS studies. Almost all patients
in the CP group completed the four courses with similar
complication rates as the BCP group. The addition of
bevacizumab did not increase the rate of AEs or SAEs
after neoadjuvant therapy compared with chemotherapy
alone. Indeed, the serious adverse event rate in BCP-
treated patients (25%) was comparable to the EORTC
Table 2
Interval debulking surgery results (mITT).
Carboplatin þ paclitaxel
(CP, n Z 37)
Bevacizumab þ carboplatin þ
paclitaxel (BCP, n Z 58)
Total (n Z 95)
IDS performed, n (%)
Yes 22 (60) 40 (69) 62 (65)
No 15 (41) 18 (31) 33 (35)
Time from first study treatment administration to IDS laparoscopy
n 32 51 83
Mean  SD, days 95.0  7.5 92.6  7.6 93.5  7.6
Range, days 82e117 61e111 61e117
Time from date of IDS laparoscopy to surgery
n 22 40 62
Mean  SD, days 1.0  3.4 1.2  3.4 1.1  3.3
Range, days 0e14 0e13 0e14
Reason IDS not performed, n
Unresectable 10 11 21
Adverse event 1 3 4
Disease progression 1 0 1
Investigator decision 1 1 2
Consent withdrawn 0 2 2
Death 1 0 1
Protocol deviation 1 1 2
IDS procedures performed, n (%)a
Omentectomy 22 (100) 40 (100) 62 (100)
Total hysterectomy with bilateral
salpingo oophorectomy
22 (100) 38 (95) 60 (97)
Pelvic lymphadenectomy 18 (82) 37 (93) 55 (89)
Para aortic lymphadenectomy 17 (77) 37 (93) 54 (87)
Pelvic peritoneum stripping 14 (64) 27 (68) 41 (66)
Diaphragm stripping/resection 12 (55) 23 (58) 35 (56)
Abdominal peritoneum stripping 9 (41) 13 (33) 22 (35)
Rectosigmoidectomy anastomosis 8 (36) 14 (35) 22 (35)
Large bowel resection 6 (27) 5 (13) 11 (18)
Splenectomy 4 (18) 6 (15) 10 (16)
Liver resection/s 1 (5) 2 (5) 3 (5)
Small bowel resection/s 2 (9) 2 (5) 4 (6)
Diverting stomia 3 (14) 2 (5) 5 (8)
Operative time (h)a
Mean  SD 5.1  1.8 5.9  1.8 5.6  1.8
Median (range) 5.0 (1.6e8.0) 5.5 (2.0e10.0) 5.3 (1.6e10.0)
Missing data, n 3 2 5
PCI total score
Mean  SD 9  6 10  7 10  7
Median (range) 10 (0e20) 11 (0e27) 10 (0e27)
Missing data, n 0 1 1
CC score, n (%)
No disease (CC Z 0) 19 (51.4) 34 (58.6) 53 (55.8)
Present, <0.25 cm (CC Z 1) 2 (5.4) 3 (5.2) 5 (5.2)
0.25 cme2.5 cm (CC Z 2) 1 (2.7) 1 (1.7) 2 (2.1)
>2.5 cm (CC Z 3) 0 2 (3.4) 2 (2.1)
Missing data (IDS not performed) 15 (40.5) 18 (31.0) 33 (34.7)
Abbreviations: CC, completeness of cytoreduction score; PCI, peritoneal cancer index; SD, standard deviation; mITT, modified intent-to-treat;
IDS, interval debulking surgery.
a Percentage are out of the number of patients in whom interval debulking surgery (IDS) was performed (carboplatin and paclitaxel, n Z 22;
bevacizumab, paclitaxel and carboplatin, n Z 40; total, n Z 62).
R. Rouzier et al. / European Journal of Cancer 70 (2017) 133e142140study (29%) [2]. The open-label design of this study had
the potential to influence perioperative decisions, but,
the expertise of the surgeons and objective evaluation of
carcinomatosis using pre-specified photographs may
have limited any potential bias.
In conclusion, adding bevacizumab to neoadjuvant
chemotherapy achieved an encouraging CRR at IDS inpatients with initially unresectable FIGO stage IIIC/IV
ovarian, tubal, or peritoneal adenocarcinoma. Our data
suggest that bevacizumab may be safely added to a
preoperative program in patients deemed non-optimally
resectable, whatever the final surgical decision. The role
of bevacizumab in this setting should be further
investigated.
Table 4
Safety summary for patients with surgery performed (neoadjuvant and IDS periods combined).
Surgery performed Carboplatin þ
paclitaxel (n Z 22)
Bevacizumab þ carboplatin þ
paclitaxel (n Z 40)
Total (n Z 62)
Examination at 30 d post-IDS, n (%)
At least one abnormal examination 13 (59) 19 (48) 32 (52)
At least one abnormal abdominal examination 11 (50) 15 (38) 26 (42)
At least one abnormal gynaecological examination 4 (18) 7 (18) 11 (18)
At least one abnormal gastrointestinal examination 2 (9) 3 (8) 5 (8)
Hospitalisation
Duration of hospitalisation in the ICU
Mean  SD, days 4.0  4.4 3.2  2.3 3.5  3.2
Median (range), days 3.0 (0e13) 3.0 (0e8) 3.0 (0e13)
No. with missing data, n 1 e 1
Total duration of hospitalisation
Mean  SD, days 15  10 12  4 13  7
Median (range), days 11 (7e51) 11 (7e24) 11 (7e51)
No. with missing data, n 1 e 1
Blood transfusion, n (%) 9 (41) 18 (45) 27 (44)
At least one postoperative complication, n (%) 8 (36) 11 (28) 19 (31)
Wound complications 2 (9) 6 (15) 8 (13)
Infectious complications 3 (14) 4 (10) 7 (11)
Gastrointestinal complications 1 (5) 4 (10) 5 (8)
Urinary complications 1 (5) 2 (5) 3 (5)
Lymphatic complications 0 2 (5) 2 (3)
Pulmonary complications 1 (5) 1 (3) 2 (3)
Bleeding complications 0 1 (3) 1 (2)
Thromboembolic complications 0 0 0
Other complications 2 (9) 1 (3) 3 (5)
Abbreviations: ICU, intensive care unit; IDS, interval debulking surgery; SD, standard deviation.
Table 3
Summary of adverse events (neoadjuvant and IDS periods combined; safety population).
n, (%) Carboplatin þ
paclitaxel (n Z 40)*
Bevacizumab þ carboplatin þ
paclitaxel (n Z 55)a
Total (n Z 95)
At least one AE 39 (98) 55 (100) 94 (99)
At least one serious AE (TEAEs) 15 (38) 14 (25) 29 (31)
Gastrointestinal disorders 5 (13) 4 (7) 9 (10)
Infections and infestations 3 (8) 5 (9) 8 (8)
Respiratory disorders 4 (10) 1 (2) 5 (5)
Blood and lymphatic disorders 1 (3) 3 (5) 4 (4)
General disorders 2 (5) 1 (2) 3 (3)
Metabolism disorders 2 (5) e 2 (2)
Vascular disorders e 2 (4) 2 (2)
Injury/procedural complications e 1 (2) 1 (1)
Neoplasms benign, malignant 1 (3) e 1 (1)
Psychiatric disorders 1 (3) e 1 (1)
Renal and urinary disorders 1 (3) e 1 (1)
Reproductive system disorders 1 (3) e 1 (1)
At least one AE grade 3 25 (63) 34 (62) 59 (62)
Main AEs grade 3b
Blood and lymphatic disorders 11 (28) 16 (29) 27 (28)
Gastrointestinal disorders 7 (18) 5 (9) 12 (13)
Vascular disorders 1 (3) 9 (16) 10 (11)
General disorders 5 (13) 4 (7) 9 (10)
Infections and infestations 3 (8) 3 (5) 6 (6)
AE leading to death 1 (3) e 1 (1%)
1 Bevacizumab-related AE e 46 (84) e
1 Paclitaxel-related AE 38 (95) 54 (98) 92 (97)
1 Carboplatin-related AE 36 (90) 50 (91) 86 (91)
Abbreviations: AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event; IDS, interval debulking surgery.
a N numbers in this table relate to actual treatment received and not study groups (i.e. if a patient was randomised to bevacizumab and
carboplatin, but only actually received chemotherapy alone they would fall into the carboplatin group in the safety population).
b With incidence 5%.
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